BIO BEHÇET’S: Optimal utilisation of biologic drugs in Behçet’s Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment

niversity of Liverpool0 个研究点目标入组 79 人开始时间: 2016年3月9日最近更新: 2020年11月24日

适应症

试验速览

暂无简介。

•1. Diagnosed to have BD by International Study Group (ISG) criteria or International Criteria for BD (ICBD)
•2. Have refractory disease as defined by the UK Centres of Excellence criteria (failure to respond to steroid and/or immunosuppressive therapy with significant or major organthreatening disease) and therefore qualify for biologic therapy with either IFX or aIFN
•3. Able to give informed consent
•4. Have not previously received a biologic agent
•5. Aged over 18 years

•1. Have a contraindication to either IFX or aIFN (eg active infection, severe liver disease, neutropenia, previous malignancy)
•2. Are likely to not comply: for example cannot attend assessments because of excessive travel requirements
•3. Are already, or likely to become, pregnant during the study
•4. Express a strong preference for one of the two potential therapies
•5. Have heart disease or severe heart failure
•6. Have been diagnosed with Multiple sclerosis
•7. Have evidence of infection with HIV

发起方

niversity of Liverpool